雄激素非依赖性前列腺癌的治疗进展  

Current Opinions on the Treatment of Androgen-independent Prostate Cancer

作　　者：管晓翔[1] 陈龙邦[1] 

机构地区：[1]南京军区南京总医院肿瘤内科,江苏南京210002

出　　处：《中华男科学杂志》2006年第11期1021-1025,共5页National Journal of Andrology

基　　金：国家自然科学基金项目(30470669)

摘　　要：前列腺癌是男性泌尿生殖系常见的恶性肿瘤之一,在我国发病率虽较低,但近年来随着人口老龄化及生活条件的改善,发病率有明显增加的趋势。几乎所有一开始对内分泌治疗敏感的前列腺癌最终都将发展成雄激素非依赖性前列腺癌(AIPC)。AIPC是指对内分泌治疗无反应或内分泌治疗后反而促进疾病进展,导致不可逆的临床进展恶化,直至患者死亡。有关AIPC的发病机制以及治疗策略仍缺乏统一的认识,现就此作一综述。Prostate cancer is a most common malignant neoplasm in males. In recent years, its incidence has been rising dramatically in China. Patients with recurrent prostate cancer may be treated with androgen deprivation strategies, but most cases will eventually develop into androgen-independent prostate cancer （AIPC）. Until recently, chemotherapy has been shown to be effecdtive in palliating the symptoms of the disease but not in improving survival. Current strategies for the treatment of AIPC have shown significant palliation, but no definitive increase in survival. Molecular mechanisms underlying the development of androgen-independent prostate cancer （AIPC） are poorly understood. However, there is growing evidence that different molecular profiles may result in the development of AIPC. In this paper, we not only review the molecular mechanism of AIPC, but also present some of the promising management principles and systemic chemotherapy options against AIPC.

关 键 词：前列腺癌 雄激素非依赖性 治疗 

分 类 号：R737.25[医药卫生—肿瘤]